Could Ozempic assist in weight loss, and who is eligible in Europe?

Ozempic for weight loss explained: semaglutide, GLP-1 receptor agonist, appetite regulation, BMI criteria, and prescribing standards.

In this episode, we outline how Ozempic (semaglutide) works and how doctors assess eligibility for weight management under EU medical guidance.

You’ll learn:

• What semaglutide is and how GLP-1 affects appetite and glucose control

• Approved indications for type 2 diabetes and weight management criteria

• Typical BMI thresholds (≥30, or ≥27 with weight-related conditions)

• Expected average weight reduction in clinical trials

• Common side effects: nausea, vomiting, diarrhoea, constipation

• Monitoring requirements: HbA1c, kidney function, cardiovascular risk

• Situations where treatment requests may be declined pending full metabolic assessment

We explain how doctors assess BMI, waist circumference, blood pressure, HbA1c, lipid profile, medical history, and previous lifestyle interventions during an online consultation in the EU. Ozempic is prescribed based on approved clinical criteria and as part of structured weight management.

This episode reflects the clinical standards used by Mobi Doctor, where metabolic consultations are reviewed by a registered physician in line with EU prescribing guidance.

Read the full guide and transcript here:

https://www.mobidoctor.eu/blog/ozempic-for-weight-loss